Mr Bingyang Zhang

During last decades, cancers are regarded as the hottest research topic. Various approaches to treat cancers have been broadly investigated. The prevention of cancers could be a better strategy than the treatment of cancers. The safety of vaccines is always the first concern in the application of cancer vaccines. Sub-unit vaccines, as a safe vaccine form, has been widely studied. However, its relatively low immune response efficiency is the main barrier limiting its development. The aim of our project is to develop a site-specific conjugated sub-unit vaccine system with high immune response efficiency to prevent desired diseases including liver cancers and prostate cancers. Designed epitopes targeting liver cancers and prostate cancers will be fused to two promising virus-like-particles (VLPs) including Hepatitis B core VLP to form novel preventive vaccines. The recombinant vaccines will be purified through chromatography and the characterizations will be evaluated. The novel recombinant VLP-based sub-unit vaccines are expected to perform safe and effective immune response to prevent liver cancers and prostate cancers.